Abstract
Patients in intensive care units (ICU) are at very high risk of invasive candidiasis associated with high mortality rate. Candida species are the third cause of septicemia. Clinical signs lack of specificity and blood cultures lack of sensitivity, and therefore the diagnosis remains a challenge. In order to improve the identification of patients with invasive candidiasis, predictive rules, biomarkers and PCR have been developed. The first part of this work describes the evolution over a ten years period in one ICU in Candida species distribution, susceptibility to antifungal drugs and consumption of antifungal agents. Changes in antifungal drug consumption were observed but they were not associated with significant changes in fungal ecology or with the emergence of resistant species. In a second part, we present a prospective, observational and bicentric study performed in 435 non-neutropenic patients in ICU. Several variables (risk factors of invasive candidiasis, Candida colonization, mannan antigen and anti-mannan antibodies) were analyzed and a predictive score of invasive candidiasis has been developed. Finally, the last part presents the development of Candida real-time PCR in blood, as well as the evaluation of a digital PCR.